Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Phase 1 Completed Mayo Clinic National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Interleukin-12 may stimulate a person's white blood cells to kill lymphoma cells. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 plus rituximab in treating patients who have non-Hodgkin's lymphoma.

Timeline

Start: 1999-10
Primary completion: 2003-06
Completion: 2003-06

Publications

Results Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002 Jan 1;99(1):67-74. doi: 10.1182/blood.v99.1.67.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Subject	interleukin-12	Protein / enzyme biologic	30 unknown	Subcutaneous
Subject	interleukin-12	Protein / enzyme biologic	300 unknown	Subcutaneous
Subject	interleukin-12	Protein / enzyme biologic	500 unknown	Subcutaneous

Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Summary

Timeline

Publications

Drugs

Indications